ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Drug-associated postpartum hemorrhage: a comprehensive disproportionality analysis based on the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Postpartum hemorrhage (PPH) is a life-threatening obstetric complication. We aimed to identify the drugs that associated with PPH based on the FDA Adverse Event Reporting System (FAERS) data, providing scientific evidence for targeted prevention of drug-related PPH risk factors. Data from 2004Q1 to 2025Q1 were extracted from FAERS, and disproportionality analysis was performed to identify potential drug signals. The Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network of information components (IC), and Empirical Bayes Geometric Mean (EBGM) were employed to identify drug-event combinations associated with PPH with signals higher than expected, and to analyze the occurrence time of adverse drug events (ADEs). A total of 1078 reports with target ADE were obtained, and 97.96% of them resulted in serious consequences. A total of 246 primary suspected drugs were identified, among which, 32 drugs across 14 systems met the signal detection requirements of this study. In terms of the number of cases, the top three drugs that induce PPH were oxytocin (ROR [95% CI]: 1985.51 [1650.23-2388.91]), dinoprostone (ROR [95% CI]: 751.23 [549.82-1026.42]), and misoprostol (ROR [95% CI]: 193.58 [140.47-266.76]). They all belong to genito urinary system and sex hormones and are commonly used in clinical settings for labor induction or PPH. More than half of the cases (n = 224, 59.26%) occurred within the first month after medication administration, and surprisingly, approximately one-fifth of the cases occurred 360 days after medication administration (n = 80, 21.16%), suggesting that the long-term risk of PPH cannot be ignored. This study identified and ranked drugs associated with PPH and analyzed the occurrence time of ADEs. We emphasized the need for personalized monitoring strategies during the perinatal period and highlighted the long-term risks of PPH caused by the use of chronic disease drugs during pregnancy.
Indexed as
Identifiers
40924106What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.